NeuroPace 2025 Q1 Earnings Beats Expectations with Net Loss Improvement of 26%
Daily EarningsWednesday, May 14, 2025 5:29 am ET
3min readNeuroPace reported its fiscal 2025 Q1 earnings on May 13th, 2025. The company exceeded analyst expectations with a quarterly loss of $0.21 per share, compared to the anticipated loss of $0.26. raised its full-year 2025 revenue guidance to a range of $93 million to $97 million, reflecting a growth of 16% to 21% over 2024. The company's strategic focus on its core RNS System product line and anticipated topline data from the pivotal study in the second half of 2025 underscore its commitment to advancing product development and achieving long-term value creation.
Revenue
NeuroPace's total revenue increased by 24.3% to $22.52 million in 2025 Q1, up from $18.12 million in 2024 Q1. This growth was driven by increased sales of the core RNS System, which treats epilepsy through responsive neurostimulation.
Earnings/Net Income
NeuroPace narrowed its losses to $0.21 per share in 2025 Q1 from a loss of $0.32 per share in 2024 Q1, showing a 34.4% improvement. The company also reduced its net loss to $-6.59 million in 2025 Q1, a 26.2% improvement over the $-8.93 million net loss reported in 2024 Q1. While the EPS remains negative, the narrowing loss reflects improved operational efficiency and positive momentum.
Price Action
The stock price of NeuroPace has dropped 4.78% during the latest trading day, has jumped 10.78% during the most recent full trading week, and has surged 21.71% month-to-date.
Post-Earnings Price Action Review
The strategy of buying NeuroPace shares when revenues miss expectations and holding for 30 days has shown promising results, delivering a 25% gain over 30 days. Backtesting further confirms the strategy's effectiveness in capturing short-term price movements following revenue misses, with a consistent 25% profit after 30 days. This approach underscores the potential for profitable short-term trading opportunities based on NeuroPace's revenue performance.
CEO Commentary
Joel Becker, Chief Executive Officer, expressed optimism about NeuroPace's future, highlighting strong first-quarter performance with $22.5 million in total revenue, a 24% increase driven by the growth of the RNS business. He emphasized the importance of expanding access to RNS therapy and noted strategic initiatives such as a $75 million equity financing and advancements in clinical development. Becker stated, “We expect a 20% plus CAGR through 2027 and remain on track for achieving cash flow breakeven by year-end 2027,” emphasizing the commitment to making the RNS System the standard-of-care for drug-resistant epilepsy patients.
Guidance
NeuroPace raised its total revenue guidance for 2025 to a range of $93 million to $97 million, reflecting a growth of approximately 16% to 21% over 2024. The company anticipates a gross margin between 73% and 75% and operating expenses ranging from $92 million to $95 million. Additionally, it expects to achieve cash flow breakeven by the end of 2027, with a projected loss from operations of $5.1 million for Q1 2025.
Additional News
In recent weeks, NeuroPace has strategically refocused on its core RNS System products, deciding to terminate its distribution relationship for SEEG products. The company is gearing up to announce topline data from the NAUTILUS pivotal study in the second half of 2025, targeting drug-resistant idiopathic generalized epilepsy, which could broaden its patient base. These strategic moves aim to enhance clinical outcomes and expand the reach of NeuroPace's innovative RNS System, positioning the company for future growth and expanded market opportunities.
Revenue
NeuroPace's total revenue increased by 24.3% to $22.52 million in 2025 Q1, up from $18.12 million in 2024 Q1. This growth was driven by increased sales of the core RNS System, which treats epilepsy through responsive neurostimulation.
Earnings/Net Income
NeuroPace narrowed its losses to $0.21 per share in 2025 Q1 from a loss of $0.32 per share in 2024 Q1, showing a 34.4% improvement. The company also reduced its net loss to $-6.59 million in 2025 Q1, a 26.2% improvement over the $-8.93 million net loss reported in 2024 Q1. While the EPS remains negative, the narrowing loss reflects improved operational efficiency and positive momentum.
Price Action
The stock price of NeuroPace has dropped 4.78% during the latest trading day, has jumped 10.78% during the most recent full trading week, and has surged 21.71% month-to-date.
Post-Earnings Price Action Review
The strategy of buying NeuroPace shares when revenues miss expectations and holding for 30 days has shown promising results, delivering a 25% gain over 30 days. Backtesting further confirms the strategy's effectiveness in capturing short-term price movements following revenue misses, with a consistent 25% profit after 30 days. This approach underscores the potential for profitable short-term trading opportunities based on NeuroPace's revenue performance.
CEO Commentary
Joel Becker, Chief Executive Officer, expressed optimism about NeuroPace's future, highlighting strong first-quarter performance with $22.5 million in total revenue, a 24% increase driven by the growth of the RNS business. He emphasized the importance of expanding access to RNS therapy and noted strategic initiatives such as a $75 million equity financing and advancements in clinical development. Becker stated, “We expect a 20% plus CAGR through 2027 and remain on track for achieving cash flow breakeven by year-end 2027,” emphasizing the commitment to making the RNS System the standard-of-care for drug-resistant epilepsy patients.
Guidance
NeuroPace raised its total revenue guidance for 2025 to a range of $93 million to $97 million, reflecting a growth of approximately 16% to 21% over 2024. The company anticipates a gross margin between 73% and 75% and operating expenses ranging from $92 million to $95 million. Additionally, it expects to achieve cash flow breakeven by the end of 2027, with a projected loss from operations of $5.1 million for Q1 2025.
Additional News
In recent weeks, NeuroPace has strategically refocused on its core RNS System products, deciding to terminate its distribution relationship for SEEG products. The company is gearing up to announce topline data from the NAUTILUS pivotal study in the second half of 2025, targeting drug-resistant idiopathic generalized epilepsy, which could broaden its patient base. These strategic moves aim to enhance clinical outcomes and expand the reach of NeuroPace's innovative RNS System, positioning the company for future growth and expanded market opportunities.
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
Comments
No comments yet